
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Defining what Gross-to-Net mean and why it is important to Life Sciences companies; Identify who in the company benefits in utilizing information from GTN; Get insights to successfully define and manage GTN process





